Hepcidin and the iron enigma in HCV infection

Virulence

Volumn 5, Issue 4, 2014, Pages 465-476

  Georgopoulou, Urania ^a   Dimitriadis, Alexios ^a   Foka, Pelagia ^a   Karamichali, Eirini ^a   Mamalaki, Avgi ^a  

^a HELLENIC PASTEUR INSTITUTE   (Greece)

Author keywords

Cell signaling pathways; Hepatitis C virus; Hepcidin; Iron; Lipid metabolism

Indexed keywords

CORE PROTEIN; FATTY ACID SYNTHASE; FERRITIN; FERROPORTIN 1; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HEPCIDIN; INTERLEUKIN 1; INTERLEUKIN 22; INTERLEUKIN 6; IRON; IRON REGULATORY FACTOR; JANUS KINASE; JANUS KINASE 2; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 4B; NONSTRUCTURAL PROTEIN 5A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RNA DIRECTED RNA POLYMERASE; STAT PROTEIN; STAT3 PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSCRIPTION FACTOR NRF2; TRANSFERRIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

APOPTOSIS; COMORBIDITY; DISEASE COURSE; ERYTHROPOIESIS; GENE; GENETIC TRANSCRIPTION; HAMP GENE; HEPATITIS C; HEPATITIS C VIRUS; HOMEOSTASIS; HUMAN; HYPOXIA; IRON HOMEOSTASIS; IRON RESPONSIVE ELEMENT; LIPID METABOLISM; LIVER CELL CARCINOMA; MACROPHAGE; NECROSIS; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; REVIEW; STELLATE CELL; UPREGULATION; ANIMAL; HEPACIVIRUS; LIVER; METABOLISM; PHYSIOLOGY; VIROLOGY;

ANIMALS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEPCIDINS; HUMANS; IRON; LIVER;

EID: 84900560973     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.28508     Document Type: Review

References (151)

1. Steinbicker AU, Muckenthaler MU. Out of balance--systemic iron homeostasis in iron-related disorders. Nutrients 2013; 5:3034-61; PMID:23917168; http://dx.doi.org/10.3390/nu5083034
2. Armitage AE, Eddowes LA, Gileadi U, Cole S, Spottiswoode N, Selvakumar TA, Ho LP, Townsend AR, Drakesmith H. Hepcidin regulation by innate immune and infectious stimuli. Blood 2011; 118:4129-39; PMID:21873546; http://dx.doi. org/10.1182/blood-2011-04-351957
3. MacKenzie EL, Iwasaki K, Tsuji Y. Intracellular iron transport and storage: from molecular mechanisms to health implications. Antioxid Redox Signal 2008; 10:997-1030; PMID:18327971; http://dx.doi. org/10.1089/ars.2007.1893
4. Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, Ishikawa I. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood 2006; 108:1381-7; PMID:16621968; http://dx.doi.org/10.1182/ blood-2005-10-4043
5. Valore EV, Ganz T. Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin. Blood Cells Mol Dis 2008; 40:132-8; PMID:17905609; http://dx.doi. org/10.1016/j.bcmd.2007.07.009
6. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276:7806-10; PMID:11113131; http://dx.doi.org/10.1074/jbc.M008922200
7. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101:2461-3; PMID:12433676; http://dx.doi.org/10.1182/blood-2002-10-3235
8. Ganz T. Hepcidin--a regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract Res Clin Haematol 2005; 18:171-82; PMID:15737883; http://dx.doi.org/10.1016/j. beha.2004.08.020
9. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306:2090-3; PMID:15514116; http://dx.doi. org/10.1126/science.1104742
10. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110:1037-44; PMID:12370282; http://dx.doi.org/10.1172/JCI0215686
11. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013; 19:850-8; PMID:23836235; http://dx.doi.org/10.1038/ nm.3184
12. Hoffman B, Liu Q. Hepatitis C viral protein translation: mechanisms and implications in developing antivirals. Liver Int 2011; 31:1449-67; PMID:21745290; http://dx.doi. org/10.1111/j.1478-3231.2011.02543.x
13. Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013; 19:837-49; PMID:23836234; http://dx.doi.org/10.1038/ nm.3248
14. Valenti L, Pulixi EA, Arosio P, Cremonesi L, Biasiotto G, Dongiovanni P, Maggioni M, Fargion S, Fracanzani AL. Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis. Haematologica 2007; 92:1037-42; PMID:17640859; http://dx.doi.org/10.3324/ haematol.11281
15. Andrews NC, Schmidt PJ. Iron homeostasis. Annu Rev Physiol 2007; 69:69-85; PMID:17014365; http://dx.doi.org/10.1146/annurev.physiol.69.031905.164337
16. Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J. Body iron metabolism and pathophysiology of iron overload. Int J Hematol 2008; 88:7-15; http://dx.doi. org/10.1007/s12185-008-0120-5; PMID:18594779
17. Abboud S, Haile DJ. A novel mammalian ironregulated protein involved in intracellular iron metabolism. J Biol Chem 2000; 275:19906-12; PMID:10747949; http://dx.doi.org/10.1074/jbc. M000713200
18. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, Paw BH, Drejer A, Barut B, Zapata A, et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 2000; 403:776-81; PMID:10693807; http://dx.doi. org/10.1038/35001596
19. McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, Miret S, Bomford A, Peters TJ, Farzaneh F, et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 2000; 5:299-309; PMID:10882071; http://dx.doi.org/10.1016/ S1097-2765(00)80425-6
20. Marro S, Chiabrando D, Messana E, Stolte J, Turco E, Tolosano E, Muckenthaler MU. Heme controls ferroportin1 (FPN1) transcription involving Bach1, Nrf2 and a MARE/ARE sequence motif at position-7007 of the FPN1 promoter. Haematologica 2010; 95:1261-8; PMID:20179090; http://dx.doi. org/10.3324/haematol.2009.020123
21. Brasse-Lagnel C, Karim Z, Letteron P, Bekri S, Bado A, Beaumont C. Intestinal DMT1 cotransporter is down-regulated by hepcidin via proteasome internalization and degradation. Gastroenterology 2011; 140:1261-71, e1; PMID:21199652; http:// dx.doi.org/10.1053/j.gastro.2010.12.037
22. Franchini M, Montagnana M, Lippi G. Hepcidin and iron metabolism: from laboratory to clinical implications. Clin Chim Acta 2010; 411:1565-9; PMID:20620132; http://dx.doi.org/10.1016/j. cca.2010.07.003
23. Gao J, Chen J, Kramer M, Tsukamoto H, Zhang AS, Enns CA. Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression. Cell Metab 2009; 9:217-27; PMID:19254567; http://dx.doi.org/10.1016/j. cmet.2009.01.010
24. Wang RH, Li C, Xu X, Zheng Y, Xiao C, Zerfas P, Cooperman S, Eckhaus M, Rouault T, Mishra L, et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab 2005; 2:399-409; PMID:16330325; http:// dx.doi.org/10.1016/j.cmet.2005.10.010
25. Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011; 117:4425-33; PMID:21346250; http:// dx.doi.org/10.1182/blood-2011-01-258467
26. Castoldi M, Muckenthaler MU. Regulation of iron homeostasis by microRNAs. Cell Mol Life Sci 2012; 2012:9; PMID:22678662
27. Zumbrennen-Bullough KWQ, Chen W, Babitt J. MicroRNA-130a Downregulates Hepcidin Expression during Iron Deficiency by Targeting ALK2. Proceedings of Fifth Congress of the International BioIron Society (IBIS), Biennial World Meeting (BioIron 2013); London, UK 14-18 April 2013 2013.
28. Zhang X, Rovin BH. Beyond anemia: hepcidin, monocytes and inflammation. Biol Chem 2013; 394:231-8; PMID:23314535; http://dx.doi. org/10.1515/bchm-2012-0217
29. Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood 2002; 99:3505-16; PMID:11986201; http://dx.doi.org/10.1182/blood.V99.10.3505
30. Cairo G, Recalcati S. Iron-regulatory proteins: molecular biology and pathophysiological implications. Expert Rev Mol Med 2007; 9:1-13; PMID:18053288; http://dx.doi.org/10.1017/ S1462399407000531
31. Wang J, Pantopoulos K. Regulation of cellular iron metabolism. Biochem J 2011; 434:365-81; PMID:21348856; http://dx.doi.org/10.1042/ BJ20101825
32. Muckenthaler MU. Fine tuning of hepcidin expression by positive and negative regulators. Cell Metab 2008; 8:1-3; PMID:18590684; http://dx.doi. org/10.1016/j.cmet.2008.06.009
33. Pietrangelo A. Metals, oxidative stress, and hepatic fibrogenesis. Semin Liver Dis 1996; 16:13-30; PMID:8723320; http://dx.doi. org/10.1055/s-2007-1007215
34. Videla LA, Fernández V, Tapia G, Varela P. Oxidative stress-mediated hepatotoxicity of iron and copper: role of Kupffer cells. Biometals 2003; 16:103-11; PMID:12572670; http://dx.doi. org/10.1023/A:1020707811707
35. Braliou GG, Verga Falzacappa MV, Chachami G, Casanovas G, Muckenthaler MU, Simos G. 2-Oxoglutarate-dependent oxygenases control hepcidin gene expression. J Hepatol 2008; 48:801-10; http://dx.doi.org/10.1016/j.jhep.2007.12.021; PMID:18313788
36. Chaston TB, Matak P, Pourvali K, Srai SK, McKie AT, Sharp PA. Hypoxia inhibits hepcidin expression in HuH7 hepatoma cells via decreased SMAD4 signaling. Am J Physiol Cell Physiol 2011; 300:C888-95; PMID:21289291; http://dx.doi.org/10.1152/ ajpcell.00121.2010
37. Deugnier Y, Turlin B. Pathology of hepatic iron overload. World J Gastroenterol 2007; 13:4755-60; PMID:17729397
38. Ko C, Siddaiah N, Berger J, Gish R, Brandhagen D, Sterling RK, Cotler SJ, Fontana RJ, McCashland TM, Han SH, et al. Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry. Liver Int 2007; 27:1394-401; PMID:17927713; http://dx.doi. org/10.1111/j.1478-3231.2007.01596.x
39. Fujita N, Sugimoto R, Takeo M, Urawa N, Mifuji R, Tanaka H, Kobayashi Y, Iwasa M, Watanabe S, Adachi Y, et al. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Mol Med 2007; 13:97-104; PMID:17515961; http://dx.doi.org/10.2119/2006-00057.Fujita
40. Sikorska K, Stalke P, Izycka-Swieszewska E, Romanowski T, Bielawski KP. The role of iron overload and HFE gene mutations in the era of pegylated interferon and ribavirin treatment of chronic hepatitis C. Med Sci Monit 2010; 16:CR137-43; PMID:20190684
41. Drakesmith H, Prentice A. Viral infection and iron metabolism. Nat Rev Microbiol 2008; 6:541-52; PMID:18552864; http://dx.doi.org/10.1038/ nrmicro1930
42. Maliken BD, Nelson JE, Kowdley KV. The hepcidin circuits act: balancing iron and inflammation. Hepatology 2011; 53:1764-6; PMID:21520181; http://dx.doi.org/10.1002/hep.24267
43. De Domenico I, Ward DM, Kaplan J. Hepcidin regulation: ironing out the details. J Clin Invest 2007; 117:1755-8; PMID:17607352; http://dx.doi. org/10.1172/JCI32701
44. Poli M, Luscieti S, Gandini V, Maccarinelli F, Finazzi D, Silvestri L, Roetto A, Arosio P. Transferrin receptor 2 and HFE regulate furin expression via mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/Erk) signaling. Implications for transferrin-dependent hepcidin regulation. Haematologica 2010; 95:1832-40; PMID:20634490; http://dx.doi.org/10.3324/ haematol.2010.027003
45. Fontana RJ, Israel J, LeClair P, Banner BF, Tortorelli K, Grace N, Levine RA, Fiarman G, Thiim M, Tavill AS, et al. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology 2000; 31:730-6; PMID:10706565; http://dx.doi. org/10.1002/hep.510310325
46. Bonkovsky HL, Naishadham D, Lambrecht RW, Chung RT, Hoefs JC, Nash SR, Rogers TE, Banner BF, Sterling RK, Donovan JA, et al.; HALT-C Trial Group. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 2006; 131:1440-51; PMID:17101320; http://dx.doi. org/10.1053/j.gastro.2006.08.036
47. Meynard D, Babitt JL, Lin HY. The liver: conductor of systemic iron balance. Blood 2014; 123:168-76; http://dx.doi.org/10.1182/blood-2013-06-427757; PMID:24200681
48. Di Bisceglie AM, Simpson LH, Lotze MT, Hoofnagle JH. Development of hepatocellular carcinoma among patients with chronic liver disease due to hepatitis C viral infection. J Clin Gastroenterol 1994; 19:222-6; PMID:7528758; http://dx.doi. org/10.1097/00004836-199410000-00011
49. Ivanov AV, Bartosch B, Smirnova OA, Isaguliants MG, Kochetkov SN. HCV and oxidative stress in the liver. Viruses 2013; 5:439-69; PMID:23358390; http://dx.doi.org/10.3390/v5020439
50. Buratti E, Tisminetzky S, Zotti M, Baralle FE. Functional analysis of the interaction between HCV 5'UTR and putative subunits of eukaryotic translation initiation factor eIF3. Nucleic Acids Res 1998; 26:3179-87; PMID:9628916; http://dx.doi. org/10.1093/nar/26.13.3179
51. Cho H, Lee HC, Jang SK, Kim YK. Iron increases translation initiation directed by internal ribosome entry site of hepatitis C virus. Virus Genes 2008; 37:154-60; http://dx.doi.org/10.1007/s11262-008-0250-0; PMID:18566883
52. Kieft JS, Zhou K, Jubin R, Doudna JA. Mechanism of ribosome recruitment by hepatitis C IRES RNA. RNA 2001; 7:194-206; PMID:11233977; http:// dx.doi.org/10.1017/S1355838201001790
53. Theurl I, Zoller H, Obrist P, Datz C, Bachmann F, Elliott RM, Weiss G. Iron regulates hepatitis C virus translation via stimulation of expression of translation initiation factor 3. J Infect Dis 2004; 190:819-25; PMID:15272411; http://dx.doi.org/10.1086/422261
54. Johnson KR, Merrick WC, Zoll WL, Zhu Y. Identification of cDNA clones for the large subunit of eukaryotic translation initiation factor 3. Comparison of homologues from human, Nicotiana tabacum, Caenorhabditis elegans, and Saccharomyces cerevisiae. J Biol Chem 1997; 272:7106-13; PMID:9054404; http://dx.doi.org/10.1074/ jbc.272.11.7106
55. Izumi N, Enomoto N, Uchihara M, Murakami T, Ono K, Noguchi O, Miyake S, Nouchi T, Fujisawa K, Marumo F, et al. Hepatic iron contents and response to interferon-alpha in patients with chronic hepatitis C. Relationship to genotypes of hepatitis C virus. Dig Dis Sci 1996; 41:989-94; PMID:8625774; http:// dx.doi.org/10.1007/BF02091542
56. Liu Y, An D, Sun R, Jin L, Wang Q. Inhibition of translation initiation factors might be the potential therapeutic targets for HCV patients with hepatic iron overload. Med Hypotheses 2012; 78:142-3; PMID:22047986; http://dx.doi.org/10.1016/j. mehy.2011.10.011
57. Bartolomei G, Cevik RE, Marcello A. Modulation of hepatitis C virus replication by iron and hepcidin in Huh7 hepatocytes. J Gen Virol 2011; 92:2072-81; PMID:21593278; http://dx.doi.org/10.1099/ vir.0.032706-0
58. Fillebeen C, Pantopoulos K. Iron inhibits replication of infectious hepatitis C virus in permissive Huh7.5.1 cells. J Hepatol 2010; 53:995-9; PMID:20813419; http://dx.doi.org/10.1016/j.jhep.2010.04.044
59. Fillebeen C, Rivas-Estilla AM, Bisaillon M, Ponka P, Muckenthaler M, Hentze MW, Koromilas AE, Pantopoulos K. Iron inactivates the RNA polymerase NS5B and suppresses subgenomic replication of hepatitis C Virus. J Biol Chem 2005; 280:9049-57; PMID:15637067; http://dx.doi.org/10.1074/jbc. M412687200
60. Pietrangelo A. Hemochromatosis gene modifies course of hepatitis C viral infection. Gastroenterology 2003; 124:1509-23; PMID:12730889; http://dx.doi. org/10.1016/S0016-5085(03)00275-0
61. Tung BY, Emond MJ, Bronner MP, Raaka SD, Cotler SJ, Kowdley KV. Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology 2003; 124:318-26; PMID:12557137; http://dx.doi.org/10.1053/ gast.2003.50046
62. Nishina S, Hino K, Korenaga M, Vecchi C, Pietrangelo A, Mizukami Y, Furutani T, Sakai A, Okuda M, Hidaka I, et al. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 2008; 134:226-38; PMID:18166355; http://dx.doi. org/10.1053/j.gastro.2007.10.011
63. Moriya K, Miyoshi H, Shinzawa S, Tsutsumi T, Fujie H, Goto K, Shintani Y, Yotsuyanagi H, Koike K. Hepatitis C virus core protein compromises iron-induced activation of antioxidants in mice and HepG2 cells. J Med Virol 2010; 82:776-92; PMID:20336713; http://dx.doi.org/10.1002/ jmv.21661
64. Choi SO, Cho YS, Kim HL, Park JW. ROS mediate the hypoxic repression of the hepcidin gene by inhibiting C/EBPalpha and STAT-3. Biochem Biophys Res Commun 2007; 356:312-7; PMID:17349976; http://dx.doi.org/10.1016/j.bbrc.2007.02.137
65. Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology 2008; 48:1420-9; PMID:18671304; http://dx.doi. org/10.1002/hep.22486
66. Nagashima M, Kudo M, Chung H, Ishikawa E, Hagiwara S, Nakatani T, Dote K. Regulatory failure of serum prohepcidin levels in patients with hepatitis C. Hepatol Res 2006; 36:288-93; PMID:16979376; http://dx.doi.org/10.1016/j.hepres.2006.08.006
67. Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW, Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 2007; 109:353-8; PMID:16946298; http://dx.doi.org/10.1182/ blood-2006-07-033969
68. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood 2006; 108:3204-9; PMID:16835372; http://dx.doi. org/10.1182/blood-2006-06-027631
69. Miyachi H, Kobayashi Y, Relja B, Fujita N, Iwasa M, Gabazza EC, Takei Y. Effect of suppressor of cytokine signaling on hepcidin production in hepatitis C virus replicon cells. Hepatol Res 2011; 41:364-74; PMID:21348906; http://dx.doi. org/10.1111/j.1872-034X.2011.00777.x
70. Fillebeen C, Muckenthaler M, Andriopoulos B, Bisaillon M, Mounir Z, Hentze MW, Koromilas AE, Pantopoulos K. Expression of the subgenomic hepatitis C virus replicon alters iron homeostasis in Huh7 cells. J Hepatol 2007; 47:12-22; PMID:17399844; http:// dx.doi.org/10.1016/j.jhep.2007.01.035
71. Kanda T, Yokosuka O, Omata M, Hepatitis C. Virus and Hepatocellular Carcinoma. Biology 2013; 2:304-16; http://dx.doi.org/10.3390/biology2010304
72. Fukutomi T, Zhou Y, Kawai S, Eguchi H, Wands JR, Li J. Hepatitis C virus core protein stimulates hepatocyte growth: correlation with upregulation of wnt-1 expression. Hepatology 2005; 41:1096-105; PMID:15841445; http://dx.doi.org/10.1002/ hep.20668
73. Kochlios E, Foka P, Tsitoura E, Doumba P, Koskinas J, Mavromara P. Effect of HCV core and core+1/S on pro-and anti-inflammatory cytokine and chemokine gene expression. Bologna, Italy: Medimond SRL Publ., 2010.
74. Tacke RS, Tosello-Trampont A, Nguyen V, Mullins DW, Hahn YS. Extracellular hepatitis C virus core protein activates STAT3 in human monocytes/ macrophages/dendritic cells via an IL-6 autocrine pathway. J Biol Chem 2011; 286:10847-55; PMID:21282107; http://dx.doi.org/10.1074/jbc. M110.217653
75. Yoshida T, Hanada T, Tokuhisa T, Kosai K, Sata M, Kohara M, Yoshimura A. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med 2002; 196:641-53; PMID:12208879; http://dx.doi.org/10.1084/ jem.20012127
76. Cozza G, Mazzorana M, Papinutto E, Bain J, Elliott M, di Maira G, Gianoncelli A, Pagano MA, Sarno S, Ruzzene M, et al. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2. Biochem J 2009; 421:387-95; PMID:19432557; http://dx.doi.org/10.1042/BJ20090069
77. Lin W, Choe WH, Hiasa Y, Kamegaya Y, Blackard JT, Schmidt EV, Chung RT. Hepatitis C virus expression suppresses interferon signaling by degrading STAT1. Gastroenterology 2005; 128:1034-41; PMID:15825084; http://dx.doi.org/10.1053/j. gastro.2005.02.006
78. Taniguchi H, Kato N, Otsuka M, Goto T, Yoshida H, Shiratori Y, Omata M. Hepatitis C virus core protein upregulates transforming growth factorbeta 1 transcription. J Med Virol 2004; 72:52-9; PMID:14635011; http://dx.doi.org/10.1002/ jmv.10545
79. Pavio N, Battaglia S, Boucreux D, Arnulf B, Sobesky R, Hermine O, Brechot C. Hepatitis C virus core variants isolated from liver tumor but not from adjacent non-tumor tissue interact with Smad3 and inhibit the TGF-beta pathway. Oncogene 2005; 24:6119-32; PMID:16007207; http://dx.doi. org/10.1038/sj.onc.1208749
80. Battaglia S, Benzoubir N, Nobilet S, Charneau P, Samuel D, Zignego AL, Atfi A, Bréchot C, Bourgeade MF. Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses from tumor suppression to epithelial-mesenchymal transition. PLoS One 2009; 4:e4355; PMID:19190755; http:// dx.doi.org/10.1371/journal.pone.0004355
81. Tsutsumi T, Suzuki T, Moriya K, Shintani Y, Fujie H, Miyoshi H, Matsuura Y, Koike K, Miyamura T. Hepatitis C virus core protein activates ERK and p38 MAPK in cooperation with ethanol in transgenic mice. Hepatology 2003; 38:820-8; PMID:14512869; http://dx.doi.org/10.1002/hep.1840380408
82. Serti E, Doumba PP, Thyphronitis G, Tsitoura P, Katsarou K, Foka P, Konstandoulakis MM, Koskinas J, Mavromara P, Georgopoulou U. Modulation of IL-2 expression after uptake of hepatitis C virus nonenveloped capsid-like particles: the role of p38 kinase. Cell Mol Life Sci 2011; 68:505-22; http://dx.doi. org/10.1007/s00018-010-0466-8; PMID:20680391
83. Hayashi J, Aoki H, Kajino K, Moriyama M, Arakawa Y, Hino O. Hepatitis C virus core protein activates the MAPK/ERK cascade synergistically with tumor promoter TPA, but not with epidermal growth factor or transforming growth factor alpha. Hepatology 2000; 32:958-61; PMID:11050045; http://dx.doi. org/10.1053/jhep.2000.19343
84. Aoyagi K, Ohue C, Iida K, Kimura T, Tanaka E, Kiyosawa K, Yagi S. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J Clin Microbiol 1999; 37:1802-8; PMID:10325327
85. Katsarou K, Lavdas AA, Tsitoura P, Serti E, Markoulatos P, Mavromara P, Georgopoulou U. Endocytosis of hepatitis C virus non-enveloped capsid-like particles induces MAPK-ERK1/2 signaling events. Cell Mol Life Sci 2010; 67:2491-506; PMID:20358251; http://dx.doi.org/10.1007/ s00018-010-0351-5
86. Zhao LJ, Wang L, Ren H, Cao J, Li L, Ke JS, Qi ZT. Hepatitis C virus E2 protein promotes human hepatoma cell proliferation through the MAPK/ERK signaling pathway via cellular receptors. Exp Cell Res 2005; 305:23-32; PMID:15777784; http://dx.doi. org/10.1016/j.yexcr.2004.12.024
87. Zhao LJ, Zhao P, Chen QL, Ren H, Pan W, Qi ZT. Mitogen-activated protein kinase signalling pathways triggered by the hepatitis C virus envelope protein E2: implications for the prevention of infection. Cell Prolif 2007; 40:508-21; PMID:17635518; http:// dx.doi.org/10.1111/j.1365-2184.2007.00453.x
88. Hassan M, Ghozlan H, Abdel-Kader O. Activation of c-Jun NH2-terminal kinase (JNK) signaling pathway is essential for the stimulation of hepatitis C virus (HCV) non-structural protein 3 (NS3)-mediated cell growth. Virology 2005; 333:324-36; PMID:15721365; http://dx.doi.org/10.1016/j. virol.2005.01.008
89. Feng DY, Sun Y, Cheng RX, Ouyang XM, Zheng H. Effect of hepatitis C virus nonstructural protein NS3 on proliferation and MAPK phosphorylation of normal hepatocyte line. World J Gastroenterol 2005; 11:2157-61; PMID:15810084
90. Pei R, Chen H, Lu L, Zhu W, Beckebaum S, Cicinnati V, Lu M, Chen X. Hepatitis C virus infection induces the expression of amphiregulin, a factor related to the activation of cellular survival pathways and required for efficient viral assembly. J Gen Virol 2011; 92:2237-48; PMID:21653755; http://dx.doi. org/10.1099/vir.0.032581-0
91. Verga-Gérard A, Porcherot M, Meyniel-Schicklin L, André P, Lotteau V, Perrin-Cocon L. Hepatitis C virus/human interactome identifies SMURF2 and the viral protease as critical elements for the control of TGF-β signaling. FASEB J 2013; 27:4027-40; PMID:23781096; http://dx.doi.org/10.1096/ fj.13-229187
92. Weizer-Stern O, Adamsky K, Margalit O, Ashur-Fabian O, Givol D, Amariglio N, Rechavi G. Hepcidin, a key regulator of iron metabolism, is transcriptionally activated by p53. Br J Haematol 2007; 138:253-62; PMID:17593032; http://dx.doi. org/10.1111/j.1365-2141.2007.06638.x
93. Sarcar B, Ghosh AK, Steele R, Ray R, Ray RB. Hepatitis C virus NS5A mediated STAT3 activation requires co-operation of Jak1 kinase. Virology 2004; 322:51-60; PMID:15063116; http://dx.doi. org/10.1016/j.virol.2004.01.008
94. Presser LD, Haskett A, Waris G. Hepatitis C virusinduced furin and thrombospondin-1 activate TGF-β1: role of TGF-β1 in HCV replication. Virology 2011; 412:284-96; PMID:21296375; http://dx.doi. org/10.1016/j.virol.2010.12.051
95. Choi SH, Hwang SB. Modulation of the transforming growth factor-beta signal transduction pathway by hepatitis C virus nonstructural 5A protein. J Biol Chem 2006; 281:7468-78; PMID:16407286; http:// dx.doi.org/10.1074/jbc.M512438200
96. Macdonald A, Crowder K, Street A, McCormick C, Saksela K, Harris M. The hepatitis C virus nonstructural NS5A protein inhibits activating protein-1 function by perturbing ras-ERK pathway signaling. J Biol Chem 2003; 278:17775-84; PMID:12621033; http://dx.doi.org/10.1074/jbc.M210900200
97. Georgopoulou U, Caravokiri K, Mavromara P. Suppression of the ERK1/2 signaling pathway from HCV NS5A protein expressed by herpes simplex recombinant viruses. Arch Virol 2003; 148:237-51; PMID:12556990; http://dx.doi.org/10.1007/ s00705-002-0925-0
98. Nelson JE, Klintworth H, Kowdley KV. Iron metabolism in Nonalcoholic Fatty Liver Disease. Curr Gastroenterol Rep 2012; 14:8-16; PMID:22124850; http://dx.doi.org/10.1007/s11894-011-0234-4
99. Aso Y, Wakabayashi S, Yamamoto R, Matsutomo R, Takebayashi K, Inukai T. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor. Diabetes Care 2005; 28:2211-6; PMID:16123492; http://dx.doi.org/10.2337/ diacare.28.9.2211
100. Younossi ZM, McCullough AJ. Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver Int 2009; 29(Suppl 2):3-12; PMID:19187068; http://dx.doi.org/10.1111/j.1478-3231.2008.01949.x
101. Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, Bartenschlager R, Wakita T, Hijikata M, Shimotohno K. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007; 9:1089-97; PMID:17721513; http://dx.doi.org/10.1038/ncb1631
102. Moriishi K, Mochizuki R, Moriya K, Miyamoto H, Mori Y, Abe T, Murata S, Tanaka K, Miyamura T, Suzuki T, et al. Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc Natl Acad Sci U S A 2007; 104:1661-6; PMID:17234812; http://dx.doi. org/10.1073/pnas.0607312104
103. Björnsson E, Angulo P. Hepatitis C and steatosis. Arch Med Res 2007; 38:621-7; PMID:17613353; http://dx.doi.org/10.1016/j.arcmed.2006.09.001
104. Roe B, Kensicki E, Mohney R, Hall WW. Metabolomic profile of hepatitis C virusinfected hepatocytes. PLoS One 2011; 6:e23641; PMID:21853158; http://dx.doi.org/10.1371/journal. pone.0023641
105. Roingeard P, Hourioux C. Hepatitis C virus core protein, lipid droplets and steatosis. J Viral Hepat 2008; 15:157-64; PMID:18086178; http://dx.doi. org/10.1111/j.1365-2893.2007.00953.x
106. Koike K, Moriya K, Matsuura Y. Animal models for hepatitis C and related liver disease. Hepatol Res 2010; 40:69-82; PMID:20156300; http://dx.doi. org/10.1111/j.1872-034X.2009.00593.x
107. Sato Y, Kato J, Takimoto R, Takada K, Kawano Y, Miyanishi K, Kobune M, Sato Y, Takayama T, Matunaga T, et al. Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor alpha expression via activation of nuclear factorkappaB. Gut 2006; 55:1801-8; PMID:16581947; http://dx.doi.org/10.1136/gut.2005.070417
108. Gómez-Gonzalo M, Benedicto I, Carretero M, Lara-Pezzi E, Maldonado-Rodríguez A, Moreno-Otero R, Lai MM, López-Cabrera M. Hepatitis C virus core protein regulates p300/CBP co-activation function. Possible role in the regulation of NF-AT1 transcriptional activity. Virology 2004; 328:120-30; PMID:15380363; http://dx.doi.org/10.1016/j. virol.2004.06.044
109. Tsutsumi T, Suzuki T, Shimoike T, Suzuki R, Moriya K, Shintani Y, Fujie H, Matsuura Y, Koike K, Miyamura T. Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity. Hepatology 2002; 35:937-46; PMID:11915042; http://dx.doi.org/10.1053/ jhep.2002.32470
110. Waris G, Felmlee DJ, Negro F, Siddiqui A. Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J Virol 2007; 81:8122-30; PMID:17507484; http://dx.doi. org/10.1128/JVI.00125-07
111. García-Mediavilla MV, Pisonero-Vaquero S, Lima-Cabello E, Benedicto I, Majano PL, Jorquera F, González-Gallego J, Sánchez-Campos S. Liver X receptor α-mediated regulation of lipogenesis by core and NS5A proteins contributes to HCV-induced liver steatosis and HCV replication. Lab Invest 2012; 92:1191-202; PMID:22641099; http://dx.doi. org/10.1038/labinvest.2012.88
112. Dharancy S, Malapel M, Perlemuter G, Roskams T, Cheng Y, Dubuquoy L, Podevin P, Conti F, Canva V, Philippe D, et al. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 2005; 128:334-42; PMID:15685545; http://dx.doi. org/10.1053/j.gastro.2004.11.016
113. Kim K, Kim KH, Ha E, Park JY, Sakamoto N, Cheong J. Hepatitis C virus NS5A protein increases hepatic lipid accumulation via induction of activation and expression of PPARgamma. FEBS Lett 2009; 583:2720-6; http://dx.doi.org/10.1016/j. febslet.2009.07.034; PMID:19631645
114. Kim KH, Hong SP, Kim K, Park MJ, Kim KJ, Cheong J. HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPARgamma. Biochem Biophys Res Commun 2007; 355:883-8; PMID:17331464; http://dx.doi. org/10.1016/j.bbrc.2007.02.044
115. Foka P, Karamichali E, Dalagiorgou G, Serti E, Doumba PP, Pissas G, Kakkanas A, Kazazi D, Kochlios E, Gaitanou M, et al. Hepatitis C virus modulates lipid regulatory factor Angiopoietin-like 3 gene expression by repressing HNF-1alpha activity. J Hepatol 2014; 60:30-8; PMID:23978712; http:// dx.doi.org/10.1016/j.jhep.2013.08.016
116. Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol 2011; 55:920-32; PMID:21718726; http://dx.doi.org/10.1016/j. jhep.2011.05.008
117. Wlazlo N, Greevenbroek MM. Lipid metabolism: a role for iron? Curr Opin Lipidol 2012; 23:258-9; PMID:22576585; http://dx.doi.org/10.1097/ MOL.0b013e328354752d
118. Haap M, Machann J, von Friedeburg C, Schick F, Stefan N, Schwenzer NF, Fritsche A, Häring HU, Thamer C. Insulin sensitivity and liver fat: role of iron load. J Clin Endocrinol Metab 2011; 96:E958-61; PMID:21430023; http://dx.doi.org/10.1210/ jc.2010-2682
119. Ahmed U, Latham PS, Oates PS. Interactions between hepatic iron and lipid metabolism with possible relevance to steatohepatitis. World J Gastroenterol 2012; 18:4651-8; PMID:23002334; http://dx.doi. org/10.3748/wjg.v18.i34.4651
120. Choi JS, Koh IU, Lee HJ, Kim WH, Song J. Effects of excess dietary iron and fat on glucose and lipid metabolism. J Nutr Biochem 2013; 24:1634-44; PMID:23643521; http://dx.doi.org/10.1016/j. jnutbio.2013.02.004
121. Lewis M, Iammarino RM. Lipemia in rodent irondeficiency anemia. J Lab Clin Med 1971; 78:546-54; PMID:5114051
122. Sherman AR. Lipogenesis in iron-deficient adult rats. Lipids 1978; 13:473-8; PMID:692295; http:// dx.doi.org/10.1007/BF02533616
123. Tosco A, Fontanella B, Danise R, Cicatiello L, Grober OM, Ravo M, Weisz A, Marzullo L. Molecular bases of copper and iron deficiencyassociated dyslipidemia: a microarray analysis of the rat intestinal transcriptome. Genes Nutr 2010; 5:1-8; PMID:19821111; http://dx.doi.org/10.1007/ s12263-009-0153-2
124. Stangl GI, Kirchgessner M. Different degrees of moderate iron deficiency modulate lipid metabolism of rats. Lipids 1998; 33:889-95; PMID:9778136; http://dx.doi.org/10.1007/s11745-998-0285-8
125. Rao GA, Crane RT, Larkin EC. Reduced plasma lecithin cholesterol acyl transferase activity in rats fed iron-deficient diets. Lipids 1983; 18:673-6; PMID:6656532; http://dx.doi.org/10.1007/ BF02534575
126. Bacon BR, Britton RS, O'Neill R. Effects of vitamin E deficiency on hepatic mitochondrial lipid peroxidation and oxidative metabolism in rats with chronic dietary iron overload. Hepatology 1989; 9:398-404; PMID:2920996; http://dx.doi. org/10.1002/hep.1840090309
127. Feldman ES, Bacon BR. Hepatic mitochondrial oxidative metabolism and lipid peroxidation in experimental hexachlorobenzene-induced porphyria with dietary carbonyl iron overload. Hepatology 1989; 9:686-92; PMID:2707735; http://dx.doi. org/10.1002/hep.1840090505
128. Ramm GA, Crawford DH, Powell LW, Walker NI, Fletcher LM, Halliday JW. Hepatic stellate cell activation in genetic haemochromatosis. Lobular distribution, effect of increasing hepatic iron and response to phlebotomy. J Hepatol 1997; 26:584-92; PMID:9075666; http://dx.doi.org/10.1016/ S0168-8278(97)80424-2
129. Bories G, Colin S, Vanhoutte J, Derudas B, Copin C, Fanchon M, Daoudi M, Belloy L, Haulon S, Zawadzki C, et al. Liver X receptor activation stimulates iron export in human alternative macrophages. Circ Res 2013; 113:1196-205; PMID:24036496; http:// dx.doi.org/10.1161/CIRCRESAHA.113.301656
130. Bonomo LdeF, Silva M, Oliveira RdeP, Silva ME, Pedrosa ML. Iron overload potentiates diet-induced hypercholesterolemia and reduces liver PPAR-α expression in hamsters. J Biochem Mol Toxicol 2012; 26:224-9; PMID:22570273; http://dx.doi. org/10.1002/jbt.21410
131. Farinati F, Cardin R, De Maria N, Della Libera G, Marafin C, Lecis E, Burra P, Floreani A, Cecchetto A, Naccarato R. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995; 22:449-56; PMID:7545199; http://dx.doi.org/10.1016/0168-8278(95)80108-1
132. Kageyama F, Kobayashi Y, Kawasaki T, Toyokuni S, Uchida K, Nakamura H. Successful interferon therapy reverses enhanced hepatic iron accumulation and lipid peroxidation in chronic hepatitis C. Am J Gastroenterol 2000; 95:1041-50; PMID:10763957; http://dx.doi.org/10.1111/j.1572-0241.2000.01979.x
133. Konishi M, Iwasa M, Araki J, Kobayashi Y, Katsuki A, Sumida Y, Nakagawa N, Kojima Y, Watanabe S, Adachi Y, et al. Increased lipid peroxidation in patients with non-alcoholic fatty liver disease and chronic hepatitis C as measured by the plasma level of 8-isoprostane. J Gastroenterol Hepatol 2006; 21:1821-5; PMID:17074020; http://dx.doi. org/10.1111/j.1440-1746.2006.04420.x
134. Barisani D, Pelucchi S, Mariani R, Galimberti S, Trombini P, Fumagalli D, Meneveri R, Nemeth E, Ganz T, Piperno A. Hepcidin and iron-related gene expression in subjects with Dysmetabolic Hepatic Iron Overload. J Hepatol 2008; 49:123-33; http://dx.doi. org/10.1016/j.jhep.2008.03.011; PMID:18462824
135. Hézode C, Cazeneuve C, Coué O, Roudot-Thoraval F, Lonjon I, Bastie A, Duvoux C, Pawlotsky JM, Zafrani ES, Amselem S, et al. Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. J Hepatol 1999; 31:979-84; PMID:10604569; http:// dx.doi.org/10.1016/S0168-8278(99)80308-0
136. Lok AS, Everhart JE, Chung RT, Kim HY, Everson GT, Hoefs JC, Greenson JK, Sterling RK, Lindsay KL, Lee WM, et al.; HALT-C Trial Group. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral longterm treatment against cirrhosis (HALT-C) trial. Hepatology 2009; 49:1828-37; PMID:19291787; http://dx.doi.org/10.1002/hep.22865
137. Macaluso FS, Maida M, Minissale MG, Li Vigni T, Attardo S, Orlando E, Petta S. Metabolic factors and chronic hepatitis C: a complex interplay. Biomed Res Int 2013; 2013:564645; PMID:23956991; http:// dx.doi.org/10.1155/2013/564645
138. Hino K, Nishina S, Hara Y. Iron metabolic disorder in chronic hepatitis C: mechanisms and relevance to hepatocarcinogenesis. J Gastroenterol Hepatol 2013; 28(Suppl 4):93-8; PMID:24251712; http://dx.doi. org/10.1111/jgh.12243
139. Adinolfi LE, Durante-Mangoni E, Zampino R, Ruggiero G. Review article: hepatitis C virusassociated steatosis--pathogenic mechanisms and clinical implications. Aliment Pharmacol Ther 2005; 22(Suppl 2):52-5; PMID:16225474; http://dx.doi. org/10.1111/j.1365-2036.2005.02597.x
140. Mueller S, Afdhal NH, Schuppan D. Iron, HCV, and liver cancer: hard metal setting the pace? Gastroenterology 2006; 130:2229-34; PMID:16762645; http://dx.doi.org/10.1053/j. gastro.2006.05.006
141. Ward DG, Roberts K, Brookes MJ, Joy H, Martin A, Ismail T, Spychal R, Iqbal T, Tselepis C. Increased hepcidin expression in colorectal carcinogenesis. World J Gastroenterol 2008; 14:1339-45; PMID:18322945; http://dx.doi.org/10.3748/ wjg.14.1339
142. Piperno A, Mariani R, Trombini P, Girelli D. Hepcidin modulation in human diseases: from research to clinic. World J Gastroenterol 2009; 15:538-51; PMID:19195055; http://dx.doi. org/10.3748/wjg.15.538
143. Tsochatzis E, Papatheodoridis GV, Koliaraki V, Hadziyannis E, Kafiri G, Manesis EK, Mamalaki A, Archimandritis AJ. Serum hepcidin levels are related to the severity of liver histological lesions in chronic hepatitis C. J Viral Hepat 2010; 17:800-6; PMID:20002304; http://dx.doi. org/10.1111/j.1365-2893.2009.01244.x
144. Mitsuyoshi H, Yasui K, Yamaguchi K, Minami M, Okanoue T, Itoh Y. Pathogenic Role of Iron Deposition in Reticuloendothelial Cells during the Development of Chronic Hepatitis C. Int J Hepatol 2013; 2013:686420; PMID:23653861; http:// dx.doi.org/10.1155/2013/686420
145. Pietrangelo A, Montosi G, Garuti C, Contri M, Giovannini F, Ceccarelli D, Masini A. Ironinduced oxidant stress in nonparenchymal liver cells: mitochondrial derangement and fibrosis in acutely iron-dosed gerbils and its prevention by silybin. J Bioenerg Biomembr 2002; 34:67-79; PMID:11860182; http://dx.doi. org/10.1023/A:1013874804911
146. Nelson JE, Wilson L, Brunt EM, Yeh MM, Kleiner DE, Unalp-Arida A, Kowdley KV; Nonalcoholic Steatohepatitis Clinical Research Network. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology 2011; 53:448-57; PMID:21274866; http://dx.doi.org/10.1002/ hep.24038
147. Nieto N, Friedman SL, Greenwel P, Cederbaum AI. CYP2E1-mediated oxidative stress induces collagen type I expression in rat hepatic stellate cells. Hepatology 1999; 30:987-96; PMID:10498651; http://dx.doi.org/10.1002/hep.510300433
148. Jaroszewicz J, Rogalska M, Flisiak I, Flisiak R. Successful antiviral therapy is associated with a decrease of serum prohepcidin in chronic hepatitis C. World J Gastroenterol 2010; 16:1747-52; PMID:20380007; http://dx.doi.org/10.3748/wjg. v16.i14.1747
149. Sebastiani G, Vario A, Ferrari A, Pistis R, Noventa F, Alberti A. Hepatic iron, liver steatosis and viral genotypes in patients with chronic hepatitis C. J Viral Hepat 2006; 13:199-205; PMID:16475996; http:// dx.doi.org/10.1111/j.1365-2893.2005.00662.x
150. Hourioux C, Patient R, Morin A, Blanchard E, Moreau A, Trassard S, Giraudeau B, Roingeard P. The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model. Gut 2007; 56:1302-8; PMID:17213339; http://dx.doi.org/10.1136/ gut.2006.108647
151. Ryan JD, Altamura S, Devitt E, Mullins S, Lawless MW, Muckenthaler MU, Crowe J. Pegylated interferon-α induced hypoferremia is associated with the immediate response to treatment in hepatitis C. Hepatology 2012; 56:492-500; PMID:22334511; http://dx.doi.org/10.1002/hep.25666